London Daily

Focus on the big picture.
Thursday, Oct 30, 2025

Covid: More than enough vaccines for under-30s, says Hancock

Covid: More than enough vaccines for under-30s, says Hancock

The UK has more than enough supply of the Pfizer and Moderna jabs to vaccinate all adults under 30, the health secretary has said.

UK vaccine advisers say people aged 18 to 29 should be offered a different vaccine due to evidence linking AstraZeneca jabs to blood clots.

Matt Hancock said the UK is on track to vaccinate all adults by 31 July.

He said the AstraZeneca jab remained safe and urged those who had received one dose to take up their second.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) said there was no proof the vaccine had caused the clots but the link was getting firmer, while the European Medicines Agency (EMA) has said the benefits of the jab outweigh the risks.

Mr Hancock said there was "no evidence" of rare blood clots after the second dose of the vaccine.

He also urged everyone to take up the offer of a first vaccine when they were called.

It comes as the UK's vaccination programme recovered after a lull over Easter, with an extra 408,396 second doses administered and 99,530 first doses. The number of people fully vaccinated is now over six million.

Another 3,030 confirmed cases were reported and 53 further deaths within 28 days of a positive test.

The health secretary sought to reassure the public and said they can have confidence in the safety system because regulators were "able to spot this extremely rare event".

"The safety system that we have around this vaccine is so sensitive that it can pick up events that are four in a million [the chance of developing a rare brain blood clot] - I'm told this is about the equivalent risk of taking a long-haul flight," he told BBC Breakfast.

There is "more than enough of the Pfizer or Moderna vaccine" for the 8.5 million adults under 30 who are yet to be vaccinated in the UK to have two doses, he said.

The UK has ordered 40 million doses of the Pfizer vaccine and 17 million of the Moderna jab and also has agreements with several other companies for jabs that are still waiting for approval, including 100 million doses from Valneva and 30 million from Janssen.

Mr Hancock said Covid was a "horrible disease" and long Covid affected people in their 20s "just a much" as any other age group, sometimes with "debilitating side effects that essentially ruin your life".

He said he was looking forward to getting vaccinated "as a healthy 42 year old" and said when the time comes "I will take whatever vaccine I am offered".

Labour leader Sir Keir Starmer also urged people to have the AstraZeneca vaccine, saying he had received the jab himself and would have the second dose.

"I think the most important thing is that we get the vaccine programme rolled out as quickly as possible - that is the surest way through this pandemic," he said.

As of Tuesday more than 31.7 million people have received a first dose of a coronavirus vaccine in the UK, with some 5.6 million having received a second shot.



The recommendation to offer alternative vaccines to younger people came after a review by the MHRA found that by the end of March 79 people had suffered rare blood clots after vaccination - 19 of whom had died.

Prof Anthony Harnden, deputy chairman of the Joint Committee on Vaccination and Immunisation (JCVI), said that both the regulators had said the AstraZeneca jab could continue to be used in all age groups.

But he said the committee, which advises the government on the vaccine rollout, had decided it felt more comfortable if the under-30 age group - which is at lower risk from Covid - was offered an alternative option.

Prof Stephen Reicher, who is a member of the Scientific Pandemic Insights Group on Behaviours (Spi-B), told BBC Radio 4's World at One the move to favour other jabs for the under-30s could dent confidence in vaccination, saying we are "not being as good in the rollout of information as we have been at the rollout of the vaccine itself".


Blood clot victim's sister urges people to get jab


Neil Astles, 59, a solicitor from Warrington, Cheshire, started to have headaches and feel nauseous about a week after receiving the Oxford-AstraZeneca vaccine on 17 March.

Around eight days later he began to lose his vision and he was taken to hospital last Friday, his sister, Dr Alison Astles, told the BBC.

Doctors found a "huge blood clot" on his brain and he died on Sunday evening,

"The human being, the sister in me, still feels absolutely furious and very angry this has happened to my brother," she said. But Dr Astles, a pharmacist, said she "strongly" believes people should continue to have the vaccine.

"Overall, we will save more lives by people having the vaccine than not. The risk of a clot is very, very small and my brother was extraordinarily unlucky."

European countries have made their own decisions on the use of the AstraZeneca vaccine with many restricting them to older age groups, while Australia has said people under the age of 50 should be given the Pfizer vaccine instead.

Prof Andrew Pollard, director of the Oxford Vaccine Group, told BBC Radio 4's Today programme now was "not the time to waiver" and said people had to put their confidence in the system.

Prof Beverley Hunt, an expert in thrombosis and haemostasis at King's College London who has been working with the MHRA on the clot cases, said we do not know if the AstraZeneca vaccine causes the blood clots.

People had been seeing doctors with "the worst headache they've ever had" four days after vaccination or sometimes later, she said, and said early treatment could improve outcomes for people.

The focus on the AstraZeneca jab comes as scientists tracking the epidemic have said there is increasing evidence that the England's vaccination programme is breaking the link between Covid-19 cases and deaths.

The React survey, run by Imperial College London, found infections had fallen by roughly two-thirds since February, but had now begun to level off.


Matt Hancock says there are "more than enough" alternatives to the AstraZeneca vaccine for the under-30s


Newsletter

Related Articles

0:00
0:00
Close
UK and Vietnam Sign Landmark Migration Deal to Fast-Track Returns of Irregular Arrivals
UK Drug-Pricing Overhaul Essential for Life-Sciences Ambition, Says GSK Chief
Princesses Beatrice and Eugenie Temporarily Leave the UK Amid Their Parents’ Royal Fallout
UK Weighs Early End to Oil and Gas Windfall Tax as Reeves Seeks Investment Commitments
UK Retail Inflation Slows as Shop Prices Fall for First Time Since Spring
Next Raises Full-Year Profit Guidance After Strong Third-Quarter Performance
Reform UK’s Lee Anderson Admits to 'Gaming' Benefits System While Advocating Crackdown
United States and South Korea Conclude Major Trade Accord Worth $350 Billion
Hurricane Melissa Strikes Cuba After Devastating Jamaica With Record Winds
Vice President Vance to Headline Turning Point USA Campus Event at Ole Miss
U.S. Targets Maritime Narco-Routes While Border Pressure to Mexico Remains Limited
Bill Gates at 70: “I Have a Real Fear of Artificial Intelligence – and Also Regret”
Elon Musk Unveils Grokipedia: An AI-Driven Alternative to Wikipedia
Saudi Arabia Unveils Vision for First-Ever "Sky Stadium" Suspended Over Desert Floor
Amazon Announces 14 000 Corporate Job Cuts as AI Investment Accelerates
UK Shop Prices Fall for First Time Since March, Food Leads the Decline
London Stock Exchange Group ADR (LNSTY) Earns Zacks Rank #1 Upgrade on Rising Earnings Outlook
Soap legend Tony Adams, long-time star of Crossroads, dies at 84
Rachel Reeves Signals Tax Increases Ahead of November Budget Amid £20-50 Billion Fiscal Gap
NatWest Past Gains of 314% Spotlight Opportunity — But Some Key Risks Remain
UK Launches ‘Golden Age’ of Nuclear with £38 Billion Sizewell C Approval
UK Announces £1.08 Billion Budget for Offshore Wind Auction to Boost 2030 Capacity
UK Seeks Steel Alliance with EU and US to Counter China’s Over-Capacity
UK Struggles to Balance China as Both Strategic Threat and Valued Trading Partner
Argentina’s Markets Surge as Milei’s Party Secures Major Win
British Journalist Sami Hamdi Detained by U.S. Authorities After Visa Revocation Amid Israel-Gaza Commentary
King Charles Unveils UK’s First LGBT+ Armed Forces Memorial at National Memorial Arboretum
At ninety-two and re-elected: Paul Biya secures eighth term in Cameroon amid unrest
Racist Incidents Against UK Nurses Surge by 55%
UK Chancellor Rachel Reeves Cites Shared Concerns With Trump Administration as Foundation for Early US-UK Trade Deal
Essentra plc: A Closer Look at a UK ‘Penny Stock’ Opportunity Amid Market Weakness
U.S. and China Near Deal to Avert Rare-Earth Export Controls Ahead of Trump-Xi Summit
Justin time: Justin Herbert Shields Madison Beer with Impressive Reflex at Lakers Game
Russia’s President Putin Declares Burevestnik Nuclear Cruise Missile Ready for Deployment
Giuffre’s Memoir Alleges Maxwell Claimed Sexual Act with Clooney
House Republicans Move to Strip NYC Mayoral Front-Runner Zohran Mamdani of U.S. Citizenship
Record-High Spoiled Ballots Signal Voter Discontent in Ireland’s 2025 Presidential Election
Philippines’ Taal Volcano Erupts Overnight with 2.4 km Ash Plume
Albania’s Virtual AI 'Minister' Diella Set to 'Birth' Eighty-Three Digital Assistants for MPs
Tesla Unveils Vision for Optimus V3 as ‘Biggest Product of All Time’, Including Surgical Capabilities
Francis Ford Coppola Auctions Luxury Watches After Self-Financed Film Flop
Convicted Sex Offender Mistakenly Freed by UK Prison Service Arrested in London
United States and China Begin Constructive Trade Negotiations Ahead of Trump–Xi Summit
U.S. Treasury Sanctions Colombia’s President Gustavo Petro over Drug-Trafficking Allegations
Miss USA Crowns Nebraska’s Audrey Eckert Amid Leadership Overhaul
‘I Am Not Done’: Kamala Harris Signals Possible 2028 White House Run
NBA Faces Integrity Crisis After Mass Arrests in Gambling Scandal
Swift Heist at the Louvre Sees Eight French Crown Jewels Stolen in Under Seven Minutes
U.S. Halts Trade Talks with Canada After Ontario Ad Using Reagan Voice Triggers Diplomatic Fallout
Microsoft AI CEO: ‘We’re making an AI that you can trust your kids to use’ — but can Microsoft rebuild its own trust before fixing the industry’s?
×